Pharma BD Deal Intelligence
A $32M stock-for-stock deal that gave Lexicon its only lasting drug engine—Coelacanth's chemistry platform yielded two FDA approvals, telotristat ethyl and sotagliflozin—though neither became a blockbuster and sotagliflozin still lacks its intended core U.S. indication 15+ years later.
Coelacanth's chemistry platform became Lexicon's only drug engine and did yield two FDA approvals, but neither became a commercial blockbuster, and the deal's own $32M price is dwarfed by decades of value destruction elsewhere in Lexicon's business.
Full analysis, sources & comparables →Lexicon Genetics said it would acquire Coelacanth Corp. in a deal valued at about $32 million, reflecting Lexicon's efforts to build its drug discovery…
Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Stock-for-stock; created Lexicon Pharmaceuticals. Below $250M threshold but strategically notable: chemistry/ADME platform; Coelacanth clients included Pfizer, Roche, Novartis.
Coelacanth's chemistry platform became Lexicon's only drug engine and did yield two FDA approvals, but neither became a commercial blockbuster, and the deal's own $32M price is dwarfed by decades of value destruction elsewhere in Lexicon's business.
Assessment window: 15yr post-close.
This deal is a platform/capability acquisition rather than an indication-specific transaction. Coelacanth Corporation, based in Princeton NJ, was a fee-for-service medicinal chemistry shop providing combinatorial chemical libraries and high-throughput ADME screens for partners including Pfizer, Roche, Novartis, DuPont, and Aventis. Lexicon Genetics acquired Coelacanth to convert its gene-knockout target discovery engine into a fully integrated small-molecule drug discovery operation.
In 2001, post-Human Genome Project genomics-platform companies (Lexicon, Human Genome Sciences, Millennium, Celera, Incyte) faced pressure to translate gene targets into drug pipelines. Pure-play chemistry CROs of the era — ArQule, Pharmacopeia, ChemBridge, Albany Molecular — competed for partnerships with Big Pharma's lead-optimization teams. Coelacanth differentiated on 'drug-like' library design plus integrated ADME profiling, signing service contracts with five top-20 pharmas. Lexicon's $32M stock-for-stock acquisition (per Justia merger agreement and GenomeWeb coverage) pulled this capability in-house, mirroring Millennium's earlier acquisition of LeukoSite/COR Therapeutics for vertical integration. The combined entity rebranded its therapeutic arm as Lexicon Pharmaceuticals and shifted from a target-licensing royalty model to internal pipeline development — a strategic pivot that ultimately produced LX4211/sotagliflozin (Inpefa). The deal validated the thesis that genomics-only business models could not capture sufficient downstream value without owned chemistry. Source: https://www.genomeweb.com/archive/lexicon-acquire-drug-discoverer-coelacanth
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Lexicon Genetics Incorporated / Coelacanth Corporation (this deal) | 2001 | $32M | 53 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals